Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month ...

The medical device company has seen its growth rate take a hit in recent quarters. DexCom blames its restructuring, but rising demand for GLP-1 drugs could be an issue. The stock's valuation has ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy right now. Overview of the Medical Devices Sector According ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Across the recent three months, 5 analysts have shared their insights on DexCom DXCM, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...